mTOR/p70S6K signal transduction pathway contributes to osteosarcoma progression and patients' prognosis

Medical Oncology

Volumn 27, Issue 4, 2010, Pages 1239-1245

  Zhou, Quan ^a   Deng, Zhansheng ^b   Zhu, Yong ^b   Long, Haitao ^b   Zhang, Shaoxian ^a   Zhao, Jiali ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinical pathology; Mammalian target of rapamycin; Osteosarcoma; p70 S6 kinase; Prognosis

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; S6 KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ADOLESCENT; ADULT; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOSARCOMA; PROGNOSIS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SURVIVAL RATE; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 78650322560     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-009-9365-y     Document Type: Article

References (28)

1. Longhi A, Errani C, De Paolis M. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32:423-36. (Pubitemid 44309249)
2. Chou AJ, Gorlick R. Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther. 2006;6:1075-85. (Pubitemid 44203385)
3. Ek E T H, Ojaimi J, Kitagawa Y, Choong P F M. Outcome of patients with osteosarcoma over 40 years of age: is angiogenesis a marker of survival? Int Semin Surg Oncol. 2006;3:7-18.
4. Huang J, Zhu B, Lu L, Lian Z, Wang Y, Yang X, et al. The expression of novel gene URG4 in osteosarcoma: correlation with patients' prognosis. Pathology. 2009;41:149-54.
5. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S, Chen X. VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol. 2009. doi:10.1016/j.suronc.2009.09. 002.
6. Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, et al. Survivin as a prognostic factor for osteosarcoma patient. Acta Histochem Cytochem. 2006;39:95-100.
7. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37:19-24. (Pubitemid 40070934)
8. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med. 2005;11:353-61. (Pubitemid 41080576)
9. Martin DE, Hall MN. The expanding TOR signaling network. Curr Opin Cell Biol. 2005;17:158-66. (Pubitemid 40380939)
10. Law BK. Rapamycin: an anti-cancer immunosuppressant? Crit Rev Oncol Hematol. 2005;56:47-60. (Pubitemid 41278645)
11. Couch FJ, et al. Localization of PS6 K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res. 1999;59:1408-11. (Pubitemid 29160100)
12. Liu L, et al. Rapamycin inhibits cell motility by suppression of mTOR mediated S6K1 and 4EBP1 pathways. Oncogene. 2006;25:7029-40. (Pubitemid 44722071)
13. Bärlund M, et al. Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J Natl Cancer Inst. 2000;92:1252-9. (Pubitemid 30627733)
14. Heinonen H, Nieminen A, Saarela M, Kallioniemi A, Klefström J, Hautaniemi S, et al. Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics. 2008;9:348-59.
15. Enneking WF, Spanier SS, Goodman MA. A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res. 1980;153:106-20. (Pubitemid 11217753)
16. Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy-study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl): 21-4. (Pubitemid 13040817)
17. Pantuck AJ, Seligson DB, Klatte T. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer. 2007;109:2257-67.
18. Kreuter M, Bieker R, Bielack SS. Prognostic relevance of increased angiogenesis in osteosarcoma. Clin Cancer Res. 2004;10:8531-7. (Pubitemid 40053420)
19. Kaya M, Wada T, Kawaguchi S. Increased pretherapeutic serum vascular endothelial growth factor in patients with early clinical relapse of osteosarcoma. Br J Cancer. 2002;86:864-9. (Pubitemid 34271020)
20. Workman P. Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment. Biochem Soc Trans. 2004;32:393-6. (Pubitemid 38582134)
21. Granville CA, Memmot RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res. 2006;12:679-89. (Pubitemid 43259846)
22. Fang Y, Vilella-Bach M, Bachmann R, Flanigan A, Chen J. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science. 2001;294:1942-5. (Pubitemid 33101594)
23. Mungamuri SK, Yang XH, Thor AD, Somasundaram K. Survival signaling by notch1: mammalian target of rapamycin (mTOR) - dependent inhibition of p53. Cancer Res. 2006;66:4715-24.
24. Majumder PK, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med. 2004;10:594-601. (Pubitemid 38796850)
25. Morgensztern D, McLeod HL. Mcleod. PI3 K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005;16:797-803. (Pubitemid 41215743)
26. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci USA. 2001;98:9666-70. (Pubitemid 32769360)
27. Beevers CS, Li F, Liu L, Huang S. Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 2006;119:757-64. (Pubitemid 44051438)
28. Hou G, Xue L, Lu Z, Fan T, Tian F, Xue Y. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Cancer Lett. 2007;253:236-48. (Pubitemid 47017539)